William Henry Howell
1860-1945 · Estadounidense · Bioquímica
Fisiólogo estadounidense en Johns Hopkins cuyo laboratorio fue responsable del aislamiento de la heparina en 1916 y la posterior caracterización de su acción anticoagulante, abriendo la era moderna de la farmacología anticoagulante dentro de la cual el legado molecular de la hirudina (Haycraft, 1884) se enmarcó finalmente.
Perfil
- Años de vida
- 1860-1945
- Nacionalidad
- American
- Época
- Principios del siglo XX
- Campo principal
- Bioquímica
Afiliaciones institucionales
- Johns Hopkins University (B.A., 1881; Ph.D. in Biology, 1884)
- Johns Hopkins University School of Medicine (Professor of Physiology, 1893-1931; Dean, 1899-1911)
- Johns Hopkins School of Hygiene and Public Health (founding co-Director with William H. Welch)
- National Academy of Sciences (member)
Contribuciones clave
- Served as Professor of Physiology and later Dean at the Johns Hopkins University School of Medicine (1893-1931), establishing one of the foremost American physiology laboratories of the early twentieth century.
- Directed the Johns Hopkins laboratory in which the second-year medical student Jay McLean, in 1916, identified the anticoagulant activity of a liver phospholipid preparation that Howell subsequently named heparin (1918).
- Continued the systematic characterization of heparin's anticoagulant action across the 1920s and 1930s, providing the laboratory groundwork for the eventual clinical development of heparin as a parenteral anticoagulant in the late 1930s and 1940s.
- Authored A Text-book of Physiology, a standard American medical-physiology reference across multiple editions in the early twentieth century, transmitting the emerging laboratory understanding of coagulation to a generation of American medical students.
- Established, through the Hopkins physiology laboratory, a sustained American scientific tradition of coagulation research that, by the late twentieth century, would converge with the molecular characterization of leech-derived anticoagulants (hirudin, antistasin) in a unified anticoagulant-pharmacology field.
Importancia para la hirudoterapia
William Henry Howell's contribution to hirudotherapy is the parallel-historical role his laboratory played in opening the modern anticoagulant-pharmacology era within which the molecular legacy of leech-derived anticoagulants — and ultimately of hirudotherapy more broadly — would be ultimately situated. John Berry Haycraft's 1884 discovery that medicinal leech extract prevents blood clotting inaugurated the molecular era of hirudotherapy research. Thirty-two years later, in 1916, the medical student Jay McLean working under Howell's direction at Johns Hopkins isolated a second naturally-occurring anticoagulant principle — heparin — from mammalian liver. The parallel between Haycraft's leech-derived anticoagulant and Howell's mammalian-derived anticoagulant established the conceptual frame within which the field of anticoagulant pharmacology developed across the twentieth century. Howell's laboratory characterization of heparin across the 1920s and 1930s — including the 1925 American Journal of Physiology paper that established heparin as a defined biochemical anticoagulant principle — provided the experimental groundwork for the eventual late-1930s and 1940s clinical introduction of parenteral heparin as the first widely-used pharmaceutical anticoagulant. The clinical heparin era subsequently shaped the conceptual environment in which the late-twentieth-century pharmaceutical development of recombinant hirudin (lepirudin, desirudin) and of synthetic direct thrombin inhibitors (bivalirudin, argatroban, dabigatran) could be rationally pursued as alternatives or complements to heparin. The American Society of Hirudotherapy regards William Henry Howell as a foundational figure of the modern anticoagulant-pharmacology era within which the molecular legacy of hirudin is situated, and as the laboratory-historical counterpart to John Berry Haycraft's 1884 Edinburgh work. Howell's role within hirudotherapy is contextual rather than direct: he did not himself work on leech-derived anticoagulants, but the laboratory environment and pharmacological framework his work established made possible the eventual integration of hirudin-derived therapeutics into contemporary anticoagulant medicine.
Publicaciones clave
- A Text-book of Physiology, for Medical Students and Physicians · Philadelphia: W. B. Saunders Company (multiple editions through 1940s) (1905)
- Two New Factors in Blood Coagulation — Heparin and Pro-Antithrombin · American Journal of Physiology (1918)
- Heparin, an Anticoagulant · American Journal of Physiology (1925)
Recursos externos
Investigación influenciada
Compuestos y áreas de investigación que se remontan a las contribuciones de esta figura:
Figuras relacionadas
John Berry Haycraft
1857-1922 · Británico (escocés)
Fisiólogo de Edimburgo que descubrió la hirudina en 1884, fundando la farmacología molecular moderna de la saliva de sanguijuela.
Carl Jacobj (Karl Jacoby)
1857-1944 · Alemán
Göttingen pharmacologist who gave the anticoagulant principle of leech extract its name, 'hirudin', patented its preparation, after which hirudin was sold commercially.
Izolda P. Baskova (Изольда Парфирьевна Баскова)
Ruso (soviético)
Moscow State University biochemist and physiologist who, with G. I. Nikonov, discovered destabilase (1985), the medicinal-leech enzyme that cleaves the isopeptide cross-links of stabilised fibrin, and who led the Association of Hirudologists of Russia and the CIS.
Robert G. Brankamp
Estadounidense
Cincinnati biochemist whose studies of leech-derived factor Xa inhibitors established the sequence of ghilanten, its heparin-binding domain and its recombinant production in yeast.